Lisha Zha1, Fabiana M S Leoratti1, Lichun He2, Mona O Mohsen3, Mark Cragg4, Federico Storni1, Monique Vogel5, Martin F Bachmann6. 1. Immunology, RIA, Inselspital, University Hospital Bern, Bern, Switzerland. 2. Biozentrum, University of Basel, Basel, Switzerland. 3. Jenner Institute, University of Oxford, Oxford, United Kingdom. 4. Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, General Hospital, University of Southampton, Southampton, United Kingdom. 5. Immunology, RIA, Inselspital, University Hospital Bern, Bern, Switzerland. Electronic address: monique.vogel@dbmr.unibe.ch. 6. Immunology, RIA, Inselspital, University Hospital Bern, Bern, Switzerland; Jenner Institute, University of Oxford, Oxford, United Kingdom. Electronic address: martin.bachmann@dbmr.unibe.ch.
Abstract
BACKGROUND: Induction of allergen-specific IgG antibodies is a critical parameter for successful allergen-specific immunotherapy. IgG antibodies can inhibit IgE-mediated mast cell activation through direct allergen neutralization or through the inhibitory receptor FcγRIIb. The affinity of IgE antibodies to the allergen has been shown to be critical for cellular activation. OBJECTIVE: Here we addressed the question of affinity thresholds of allergen-specific IgG antibodies for inhibition of mast cell activation using 2 different mAbs against the major cat allergen Fel d 1 both in vitro and in vivo in mice. METHODS: Sequences of the 2 high-affinity mAbs were back-mutated to germline, resulting in low-affinity (10-7 mol/L) antibodies of the exact same specificity. RESULTS: Using these newly generated recombinant antibodies, we demonstrate that low-affinity antibodies are still able to inhibit mast cell activation through FcγRIIb but do not neutralize the allergen. CONCLUSION: Antibody affinity dictates the mechanism of mast cell inhibition, and IgG antibodies triggering the inhibitory FcγRIIb pathway can show a broader cross-reactivity pattern than previously thought. This indicates that allergen-specific immunotherapy generates a larger protective umbrella of inhibitory IgG antibodies than previously appreciated.
BACKGROUND: Induction of allergen-specific IgG antibodies is a critical parameter for successful allergen-specific immunotherapy. IgG antibodies can inhibit IgE-mediated mast cell activation through direct allergen neutralization or through the inhibitory receptor FcγRIIb. The affinity of IgE antibodies to the allergen has been shown to be critical for cellular activation. OBJECTIVE: Here we addressed the question of affinity thresholds of allergen-specific IgG antibodies for inhibition of mast cell activation using 2 different mAbs against the major cat allergen Fel d 1 both in vitro and in vivo in mice. METHODS: Sequences of the 2 high-affinity mAbs were back-mutated to germline, resulting in low-affinity (10-7 mol/L) antibodies of the exact same specificity. RESULTS: Using these newly generated recombinant antibodies, we demonstrate that low-affinity antibodies are still able to inhibit mast cell activation through FcγRIIb but do not neutralize the allergen. CONCLUSION: Antibody affinity dictates the mechanism of mast cell inhibition, and IgG antibodies triggering the inhibitory FcγRIIb pathway can show a broader cross-reactivity pattern than previously thought. This indicates that allergen-specific immunotherapy generates a larger protective umbrella of inhibitory IgG antibodies than previously appreciated.
Authors: Federico Storni; Gustavo Cabral-Miranda; Elisa Roesti; Lisha Zha; Paul Engeroff; Andris Zeltins; Mark Cragg; Monique Vogel; Martin F Bachmann Journal: Int Arch Allergy Immunol Date: 2020-03-10 Impact factor: 2.749
Authors: Oliver T Burton; Alexandra Epp; Manoussa E Fanny; Samuel J Miller; Amanda J Stranks; Jessica E Teague; Rachael A Clark; Matt van de Rijn; Hans C Oettgen Journal: Front Immunol Date: 2018-06-06 Impact factor: 7.561
Authors: Anuya Paranjape; Mindy Tsai; Kaori Mukai; Ramona A Hoh; Shilpa A Joshi; R Sharon Chinthrajah; Kari C Nadeau; Scott D Boyd; Stephen J Galli Journal: Front Immunol Date: 2020-12-14 Impact factor: 7.561
Authors: Genghao Chen; Ellen L Shrock; Mamie Z Li; Jonathan M Spergel; Kari C Nadeau; Jacqueline A Pongracic; Dale T Umetsu; Rima Rachid; Andrew J MacGinnitie; Wanda Phipatanakul; Lynda Schneider; Hans C Oettgen; Stephen J Elledge Journal: Cell Rep Med Date: 2021-10-19
Authors: Sonja Heine; Antonio Aguilar-Pimentel; Dennis Russkamp; Francesca Alessandrini; Valerie Gailus-Durner; Helmut Fuchs; Markus Ollert; Reinhard Bredehorst; Caspar Ohnmacht; Ulrich M Zissler; Martin Hrabě de Angelis; Carsten B Schmidt-Weber; Simon Blank Journal: Pharmaceutics Date: 2022-07-22 Impact factor: 6.525